TREATMENT TREATMENT FAILURE AND IMMUNORESISTANCE IN BOTULINUM TOXIN THERAPY
- Authors: Timerbaeva S.1
-
Affiliations:
- Neurology Research Center, Russian Academy of Medical Sciences
- Issue: Vol 23, No 4 (2012)
- Pages: 98-102
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115506
- ID: 115506
Cite item
Open Access
Access granted
Abstract
Botulinum toxin therapy is an effective treatment for diseases accompanied by muscle spasms. There may be treatment failures in rare cases. Immunoresistance is one of the reasons for secondary inefficiency of botulinum toxin therapy.
Full Text
About the authors
S. Timerbaeva
Neurology Research Center, Russian Academy of Medical Sciences
Email: sofia@neurology.ru
Candidate of Medical Sciences Moscow
References
- Birklein F., Erbguth F. Sudomotor testing discriminates between subjects with and without antibodies against botulinum toxin A - a preliminary observation // Mov. Disord. - 2000; 15 (1): 146-149.
- Brin M., Comella C., Jankovic J. et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay // Mov. Disord. - 2008; 23 (10): 1353-1360.
- Cordivari C., Misra V. P., Vincent A. et al. Secondary Nonresponsiveness to Botulinum Toxin A in Cervical Dystonia: The Role of Electromyogram-Guided Injections, Botulinum Toxin A Antibody Assay, and the Extensor Digitorum Brevis Test // Mov. Disord. - 2006; 21 (10): 1737-1741.
- Dressler D., Dimberger G. Botulinum Toxin Antibody Testing: Comparison between the Immunoprecipitation Assay and the Mouse Diaphragm Assay // Eur. Neurol. - 2001; 45 (4): 257-260.
- Dressler D., Bigalke H. Botulinum toxin antibody type A titres after cessation of botulinum toxin therapy // Mov. Disord. - 2002; 17 (1): 170-173.
- Dressler D., Münchau A., Bhatia K. et al. Antibody-Induced Botulinum Toxin Therapy Failure: Can It Be Overcome by Increased Botulinum Toxin Doses? // Eur. Neurol. - 2002; 47 (2): 118-121. 4'2012 ВРАЧ , 0
- Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy // Mov. Disord. - 2004; 19 (8): 92-100.
- Dressler D., Lange M., Bigalke H. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B // Mov. Disord. - 2005; 20 (12): 1617-1619.
- Dressler D., Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc // Eur. J. Neurol. - 2006; 13 (1): 11-15.
- Frevert J. Xeomin: an innovative new botulinum toxin type A // Eur. J. Neurol. -2009; 16 (2): 11-13.
- Frevert J., Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? // Biologics. - 2010; 9 (4): 325-332.
- Gelb D., Yoshimura D., Olney R. et al. Change in pattern of muscle activity following botulinum toxin injections for torticollis // Ann. Neurol. - 1991; 29; 370-376.
- Hanna P., Jankovic J., Vincent A. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies // J. Neurol. Neurosurg. Psychiatry. - 1999; 66 (5): 612-616.
- Koman L., Brashear A., Rosenfeld S. et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial // Pediatrics. - 2001; 108 (5): 1062-1071.
- Lawrence I., Moy R. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A // Aesthet. Surg. J. - 2009; 29 (6): 66-71.
- Lee J., Yokota K., Arimitsu H. et al. Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutinin // Microbiology. - 2005; 151 (11): 3739-3747.
- Moore P., Naumann M. General and clinical aspects of treatment with botulinum toxin. In: Moore P., Naumann M., editors. Handbook of botulinum toxin treatment, Second ed. Malden, Mass: Blackwell Science. - 2003: 28-75.
- Müller K., Mix E., Adib Saberi F. et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity // J. Neural. Transm. - 2009; 116 (5): 579-585.
- Naumann M., Carruthers A., Carruthers J. et al. Meta-analysis of neutralizing antibodyconversionwithonabotulinumtoxinA(BOTOX®)acrossmultipleindications//Mov. Disord. - 2010; 25 (13): 2211-2218.
Supplementary files
